Is Spravato Covered by Insurance? What You Need to Know

Do Most Insurance Plans Cover Spravato?

Spravato (esketamine nasal spray) received FDA approval in 2019 for treatment-resistant depression and major depressive disorder with acute suicidal ideation. Because it holds FDA approval, it is eligible for formulary inclusion by commercial insurers, Medicare, and Medicaid. Regulatory status differentiates it from off-label ketamine formulations.

Most large commercial carriers, including Blue Cross Blue Shield, Aetna, Cigna, and UnitedHealthcare, include Spravato on their formulary. Insurers typically classify it as a specialty tier drug. Coverage is almost always subject to prior authorization and step therapy, which requires documented failure of two or more oral antidepressants.

Medicare Part B generally covers Spravato because a healthcare professional administers it in a supervised clinical setting using a buy-and-bill model. Medicare typically covers 80% of the approved amount after you meet the Part B deductible. Medicaid coverage varies by state. Many state Medicaid programs cover Spravato, but formulary placement and preferred provider networks differ significantly.

The short answer is yes, most major insurance plans do cover Spravato. "Covered" is a starting point, however, not a guarantee of affordable or accessible care.

Why "Covered by Insurance" Doesn't Mean the Same Thing for Every Patient

Insurance coverage for Spravato depends on benefit design, cost-sharing rules, network restrictions, and site-of-care requirements. These variables produce very different financial and logistical outcomes depending on your specific plan.

• Deductible status: A patient early in their plan year with a high deductible may pay full price for initial sessions until that deductible is met. Someone who has already met their deductible may owe only coinsurance.
• Coinsurance vs. copay: Some plans charge a flat copay per visit. Others charge a percentage of the total allowed amount, known as coinsurance, which can be substantial for a high-cost specialty drug.
• Medical benefit vs. pharmacy benefit: Spravato may be classified under either benefit type depending on the plan. Benefit classification affects which cost-sharing rules apply and how prior authorization is handled.
• Network restrictions: If the nearest REMS-certified site is out-of-network, you may face higher cost-sharing or no coverage at all.
• Diagnosis thresholds: Plans may define treatment-resistant depression differently. Some insurers require more documentation than others before authorizing coverage.

Before starting Spravato, review your specific plan's benefit design to understand what you will actually owe per session.

What Insurance Companies Require for Spravato Coverage

Prior authorization is the process by which an insurer reviews medical documentation before agreeing to pay for a prescribed therapy. For Spravato, insurers make this process more involved than for most medications because of the drug's cost, REMS requirements, and narrow approved indications.

Before approving coverage, insurers require documentation that goes well beyond a standard prescription.

1. Confirmed diagnosis: You must have treatment-resistant depression or major depressive disorder with active suicidal ideation. The prescribing provider must document the specific medications tried, doses, durations, and reasons for failure.
2. Prior authorization submission: The prescribing physician submits medical records, diagnosis codes, and a letter of necessity. Some insurers use standardized forms, while others require narrative justification.
3. REMS-certified site of care: Spravato can only be dispensed and administered at sites enrolled in the Spravato REMS program. The insurer may verify that the planned site holds current REMS certification.
4. Concurrent oral antidepressant: Spravato's FDA label specifies use in conjunction with an oral antidepressant. Insurers may require documentation that you are currently taking one.
5. Ongoing reauthorization: Many plans require periodic reauthorization every three to six months. Reauthorization requires updated documentation showing continued necessity and therapeutic response.

Prior authorization for Spravato is one of the more documentation-intensive processes in psychiatric care. Denials on first submission are common, and the review can take days to weeks. You should ask your provider's office to initiate prior authorization as early as possible and understand your appeal rights before the first scheduled session.

What Spravato Actually Costs and Why Insurers Pay Close Attention

Spravato is one of the higher-cost medications in psychiatry. Its pricing structure, combined with mandatory in-clinic administration and monitoring, creates a total per-session cost that insurers scrutinize carefully.

Three cost layers stack on top of each other in every Spravato session.

• Drug cost: The wholesale acquisition cost for Spravato runs approximately $882 to $1,319 per session depending on the dose.⁸ During the standard induction phase of twice-weekly sessions for four weeks, drug costs alone can reach roughly $7,058 to $10,555 before any facility charges.
• Administration and monitoring fees: Each session requires a healthcare professional to administer the nasal spray and monitor you for at least two hours post-dose. The facility charges a separate administration fee and may bill for the monitoring visit as a distinct service.
• Facility costs: REMS-certified sites must maintain specific infrastructure, staff training, and reporting systems. Clinics typically pass these operational costs through to the patient or insurer.

Insurers pay close attention because the combination of high drug cost, mandatory in-person administration, and indefinite maintenance creates a long-term financial commitment. High costs trigger utilization management controls like step therapy and reauthorization. The sticker price of Spravato is only part of the picture, as facility fees and monitoring charges contribute significantly to the total cost.

How to Check if Your Insurance Covers Spravato

Verifying Spravato coverage requires checking multiple layers of your insurance plan, not just whether the drug name appears on a formulary list.

1. Determine your benefit category: Call the number on the back of your insurance card and ask if Spravato falls under your medical benefit or pharmacy benefit. Benefit type determines which cost-sharing rules apply.
2. Ask about prior authorization requirements: Confirm what documentation your provider needs to submit and how long the review process typically takes.
3. Verify your treatment site: Ensure your planned treatment site is in-network and REMS-certified. Out-of-network sites may result in higher cost-sharing or no coverage.
4. Request a cost estimate: Ask your insurer for the expected patient responsibility per session, including both the drug cost and the administration fee. Ask whether you have met your deductible for the current plan year.
5. Ask about Medicare or Medicaid specifics: Medicare Part B typically covers Spravato at 80% after the deductible. Medicaid coverage and prior authorization rules vary by state, so contact your state office directly.
6. Confirm reauthorization timelines: Ask how often the insurer requires updated documentation to continue coverage.

Do not assume coverage based on a formulary listing alone. A brief call to your insurer using these specific questions can prevent unexpected bills after treatment begins.

How Much Does Spravato Cost With and Without Insurance?

What you actually pay for Spravato hinges on three variables: insurance status, plan type, and treatment phase.

Without insurance, the drug cost per session is approximately $882 for the 56 mg dose and $1,319 for the 84 mg dose.⁸ Administration and monitoring fees vary by clinic but can add several hundred dollars per session. A full induction course of eight sessions at the 84 mg dose could cost $10,555 or more in drug costs alone, before facility fees are added. Maintenance sessions continue indefinitely, adding ongoing costs.

With commercial insurance, you may owe a copay or coinsurance per session. A 20% coinsurance on a $1,319 drug cost equals approximately $264 per session before facility fees.⁸ Patients who have not yet met their annual deductible may pay the full allowed amount for initial sessions. Medicare Part B typically covers 80% after the annual deductible, leaving the patient responsible for approximately 20% of the approved amount. The SPRAVATO withMe savings program may reduce copays for eligible commercially insured patients, though manufacturer copay cards generally cannot be used with government-funded insurance.

There are also hidden costs beyond the copay to consider.

• Time commitment: Each session requires at least two hours on-site, and most REMS-certified clinics operate during weekday business hours.
• Time off work: During the four-week induction phase, patients attend twice-weekly sessions, potentially requiring eight partial workdays off.
• Transportation: Patients cannot drive themselves after a session. Rideshare, taxi, or a companion driver is a near-requirement.
• Financial impact: Transportation, parking, and lost wages for hourly or contract workers add to the true out-of-pocket burden.

Even with insurance, the total cost of a Spravato course extends well beyond the copay. You should factor in time off work, transportation, and the frequency of visits when evaluating whether Spravato is financially sustainable.

When Insurance Won't Cover Spravato: Who Gets Left Out and Why

Many patients with formulary coverage for Spravato still cannot access treatment because of medical eligibility criteria, geographic barriers, and limitations of the REMS distribution model.

Patients are excluded from Spravato access for reasons that insurance coverage alone cannot address.

• Diagnosis does not meet criteria: Patients with depression, anxiety, or PTSD who have not failed two or more oral antidepressants in the current episode do not qualify under most plans. Patients whose primary diagnosis is anxiety or PTSD are outside Spravato's approved indications, though ketamine for PTSD represents a separate and growing area of clinical research.
• Prior authorization denied: Documentation gaps, insufficient trial history, or insurer-specific interpretation of an adequate trial can result in denial. Appeals are possible but add weeks or months of delay.
• Geographic access: Spravato can only be administered at REMS-certified sites. People in rural areas or states with few certified sites may face long round trips per session, creating a practical barrier that insurance coverage alone cannot solve.
• Schedule and work constraints: Twice-weekly clinic visits during business hours are not feasible for many hourly workers, caregivers, or patients without flexible schedules.
• Cost-sharing burden: Even with coverage, high deductibles or coinsurance can make treatment unaffordable, particularly during the high-frequency induction phase.

For patients who do not meet Spravato's narrow eligibility criteria, lack a nearby REMS-certified site, or find the in-clinic time commitment unsustainable, at-home ketamine therapy offers a medically established alternative pathway. Ketamine itself has been FDA-approved as an anesthetic since 1970 and has been on the World Health Organization List of Essential Medicines since 1985.^1,2 Ketamine, the parent molecule of esketamine, has a substantial body of peer-reviewed research supporting its use for depression and anxiety.³ At-home ketamine therapy under provider supervision provides access to the same therapeutic mechanism without the geographic, scheduling, and diagnostic gatekeeping constraints of Spravato. At-home care means no facility requirement, no clinic schedule, and no transportation dependency.

Mindbloom is a specific, evidence-backed provider of supervised at-home ketamine therapy. In a peer-reviewed study of 11,441 Mindbloom patients published in the Journal of Affective Disorders, 89% reported improvement in depression symptoms.⁴ Mindbloom's reported depression response rate of 56.4% is comparable to or modestly exceeds rates reported in selected IV ketamine studies, though cross-study comparisons should be interpreted with caution given differences in study design, patient population, and outcome measures.^4,5

Mindbloom has facilitated over 800,000 supervised sessions and published two of the largest peer-reviewed studies of at-home ketamine therapy to date.^4,6 Mindbloom offers both sublingual tablets and subcutaneous injectables. Programs include provider consults, guide coaching, integration circles, and app-based support.

Mindbloom's at-home ketamine therapy starts at $165 per session, with programs billed in monthly installments. For example, a 6-session program is $215 per session, billed as $430 per month for 3 months. Returning clients pay as little as $129 per session with an 18-session program. For individuals excluded from Spravato by criteria, geography, or logistics, supervised at-home ketamine therapy is a different care approach with its own evidence base that is, for many patients, a better fit.

Conclusion

Spravato is covered by most major insurance plans, but coverage alone does not determine whether treatment is affordable, accessible, or practical for a given patient. The combination of prior authorization requirements, narrow diagnostic criteria, REMS site-of-care mandates, and the time and cost burden of twice-weekly in-clinic visits means that many patients who could benefit from ketamine-based treatment are effectively excluded from Spravato. For those patients, protocol-driven at-home ketamine therapy under physician oversight offers an evidence-based pathway to the same therapeutic mechanism. You should verify your specific coverage using the checklist provided in this article and explore all available options to find the right fit for your needs.

Important Safety Information

Ketamine is not FDA-approved for PTSD, depression, or anxiety. Common side effects include dissociation, increased blood pressure, nausea, dizziness, and cognitive impairment. Ketamine has abuse potential and is not appropriate for patients with uncontrolled hypertension, psychotic disorders, or substance use disorders. Do not drive or operate machinery until the day after treatment. Individual results may vary. Full safety information: www.mindbloom.com/safety-information

Off-Label Use Disclosure

Ketamine is FDA-approved only as an anesthetic. Use for mental health conditions represents off-label prescribing by licensed clinicians based on clinical judgment. Schedule III Controlled Substance - DEA regulations apply.